View the content of this email online

Flash Therapeutics establishes its new 800 m2 biomanufacturing platform in Toulouse

Pierre Fabre
Flash Therapeutics doubles its clinical batch production capacity by 2022 and expand to large-scale batch manufacturing starting 2023
Separator

Dear Partners,

 

Flash Therapeutics is accelerating the ramp up of its biomanufacturing capabilities to meet the growing demand for gene and cell therapies. As a CDMO with 16 years expertise in lentiviral transfer technologies in DNA and RNA, we offer large scale GMP clinical batches.

 

Flash Therapeutics has signed a 3-year investment agreement of 15M€ with TechLife and Elaia Partners to double our infrastructure and production capacity.  This expansion has required to offer state-of-the-art capabilities in process development and manufacturing plan of lentiviral vectors.

 

Fully dedicated to serving customers from both research and clinical communities, this scale-up will enable us to continue to provide long-term support to all our customers and their projects, by being a key international industrial partner for gene and cell therapy programs (genetics, infectious and cancer diseases) and vaccines.

 

Since August 25th, we have moved our 40 employees in a module separate from that of the Pierre Fabre Innovation Centre in Toulouse (France). Here is our new address: 
 

Flash Therapeutics
Centre de Recherche Langlade
3 avenue Hubert Curien
31100 Toulouse - France

 

Pascale Bouillé, President.

Learn more

Click Here

Follow us

Twitter Flash Therapeutics LinkedIn Flash Therapeutics Youtube Flash Therapeutics Google + Flash Therapeutics
www.flashtherapeutics.com
© Flash Therapeutics 2018

Click here to unsuscribe from the mailing list